| 摘要 |
<p>A ziprasidone formulation containing at least (a) one ziprasidone compound and at least an excipient component (b) that includes at least one of (i) one or more of a mono-, di-, or tri-ester of C12-24fatty acids and glycerol, in which each fatty acid group is chosen independently of the others, or mixtures thereof; and/or (ii) one or more mono- or di-esters of C12.24fatty acids and polyC2-3alkyleglycol, in which each fatty acid group is chosen independently of the others, or mixtures thereof; and/or (iii) a TPGS (tocopherol-succinic acid- polyethyleneglycol); and where this component (b) may optionally include (iv) optionally free polyC2-3alkyleglycol; (v) optionally free glycerol; and (vi) optionally free fatty acids having 12-24 carbon atoms; and (vii) mixtures thereof; the formulation further comprising (c) at least one surfactant selected from anionic and non- ionionic surfactants and still further comprising (d) at least one hydroxylalkyl alkylcellulose in which each alkyl group and each hydroxyalkyl group independently has from 1 to 4 carbon atoms. The formulation achieves improved dissolution and bioavalability of the formulation. Reduction in side effect profile and increased efficacy and utility in additional indications are also disclosed.</p> |
